1. Nussenblatt RB, Whitecup SM, Palestine AG. Uveitis, Fundamentals and Clinical practice. 2nd ed.St. Louis: Mosby;1996. p. 18–152.
2. Becker MD, Adamus G, Davey MP, Rosenbaum JT. The role of T cells in autoimmune uveitis. Ocul Immunol Inflamm. 2000; 8:93–100.
Article
3. Boyd SR, Young S, Lightman S. Immunopathology of the noninfectious posterior and intermediate uveitides. Surv Ophthalmol. 2001; 46:209–33.
Article
4. Illei GG, Lipsky PE. Novel, non-antigenic-specific therapeutic approaches to autoimmune/inflammatory disease. Curr Opin Immunol. 2000; 12:712–8.
5. Brandt J, Haibel H, Cornely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum. 2000; 43:1346–52.
6. Baert FJ, D'Haens GR, Peeters M, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology. 1999; 116:22–8.
7. Elliot MJ, Maini RN, Feldmann M, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994; 344:1105–10.
8. Jaffe GJ, Yang CS, Wang XC, et al. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology. 1998; 105:46–56.
Article
9. Aydin E, Kazi AA, Peyman GA, Esfahani MR. Intravitreal toxicity of moxifloxacin. Retina. 2006; 26:187–90.
Article
10. Ishikawa T, Hokama H, Katagiri Y, et al. Effects of intravitreal injection of tacrolimus (FK506) in experimental uveitis. Curr Eye Res. 2005; 30:93–101.
Article
11. Agarwal RK, Caspi RR. Rodent models of experimental autoimmune uveitis. Methods Mol Med. 2004; 102:395–419.
Article
12. Nussenblatt RB. The natural history of uveitis. Int Ophthalmol. 1990; 14:303–8.
Article
13. Bamforth SD, Lightman S, Greenwood J. The effect of TNF-a and IL-6 on the permeability of the rat blood-retinal barrier in vivo. Acta Neuropathol. 1996; 32:624–32.
14. Koizumi K, Poulaki V, Doehmen S, et al. Contribution of TNF-ato leukocyte adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo. Invest Ophthalmol Vis Sci. 2003; 44:2184–91.
15. Sartani G, Silver PB, Rizzo LV, et al. Anti-tumor necrosis factor alpha theraphy suppresses the induction of experimental autoimmune uveoretinitis in mice inhibiting antigen priming. Invest Ophthalmol Vis Sci. 1996; 37:2211–8.
16. Feldman M, Taylor P, Paleolog E, et al. Anti-TNFa therapy is useful in rheumatoid arthritis and Crohn's disease: Analysis of the mechanism of action predicts utility in other disease. Transplantation proceeding. 1998; 30:4126–7.
17. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet. 2001; 358:295–6.
Article
18. Sfikakis PP. Behcet's disease: a new target for anti-tumor necrosis factor treatment. Ann Rheum Dis. 2002; 61:51–3.
19. Sfikakis PP, Kaklamanis PH, Elezologlou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behget's disease. Ann Intern Med. 2004; 140:404–6.
20. Triolo G, Vadala M, Accardo-Palumbo A, et al. Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behcet's disease. Ann Rheum Dis. 2002; 61:560–1.
Article
21. Hwang JH, Shin SY. Anti-tumor necrosis factor monoclonal antibody treatment for Chronic Behcet's disease: 3 cases. J Korean Ophthalmol Soc. 2005; 46:1405–10.
22. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005; 123:903–12.
23. Joseph A, Raj D, Dua HS, et al. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology. 200l; 110:1449–53.
Article
24. Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology. 2005; 129:1117–20.
Article
25. Strong BY, Erny BC, Herzenberg H, Razzeca KJ. Retrobulbar optic neuritis associated with infliximab in a patient with Crohn disease. Ann Intern Med. 2004; 140:34.
Article
26. Foroozan R, Buono LM, Sergott RC, Savino PJ. Retrobulbar optic neuritis associated with infliximab. Arch Ophthalmol. 2002; 120:985–7.
27. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol. 2004; 31:1362–8.